Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOS1 | Q07889 | 9/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.35 |
| ▸ | FEN1 | P39748 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.33 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4841972 | 0.92 | SOS1 (0.44) | SOS1HTR2CKCNH2DRD2HTR6 | |
| SCHEMBL4853070 | 0.91 | HTR2C (0.38) | SOS1HTR2CKDM1A | |
| SCHEMBL5201999 | 0.89 | EPHX2 (0.44) | — | |
| SCHEMBL5201005 | 0.84 | HTR2C (0.34) | SOS1HTR2CKDM1APIM1 | |
| SCHEMBL4842921 | 0.82 | HTR2C (0.38) | SOS1HTR2CKDM1APIM1 | |
| SCHEMBL5185302 | 0.80 | TRPV1 (0.40) | — | |
| SCHEMBL4843896 | 0.74 | TRPV1 (0.44) | — | |
| SCHEMBL4847436 | 0.65 | HTR2C (0.36) | SOS1HTR2CPIM1 | |
| SCHEMBL68342 | 0.65 | PIM1 (0.41) | HTR2CKCNH2PIM1 | |
| SCHEMBL4849012 | 0.65 | TRPV1 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7439360-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2008-10-21 | — | — | US | disclosed |
| US-7439360-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2008-10-21 | — | — | US | disclosed |
| EP-1802605-A1 | IMIDAZOLE DERIVATIVES AS VANILLOID RECEPTOR LIGANDS | Amgen, Inc (US) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006044527-A1 | IMIDAZOLE DERIVATIVES AS VANILLOID RECEPTOR LIGANDS | AMGEN INC. (US) | 2006-04-27 | — | — | WO | disclosed |
| US-20060084640-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2006-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084640-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV3, TRPV2 | SOS1 2211/4885HTR2C 119/4885ALOX5AP 1816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.